NeuroSense Therapeutics: Canadian Regulatory Progress Paves Way for Pharma Partnership and Potential $100-150M Peak Revenue

NeuroSense Therapeutics has completed a pre-submission meeting with Health Canada for its ALS drug PrimeC, potentially paving the way for fast-track approval. The positive tone from the meeting could accelerate Canadian approval and advance negotiations for a partnership with a global pharma player. With strong Phase 2b data and peak revenue estimates of $100-150M from the Canadian market, this milestone could be a catalyst for regulatory momentum and investor revaluation.